has decided to embark on the path of fine-tuning and developing rhNGF in its formulation for clinical use, at its own biotech facility in L’Aquila. and in Naples, where there are the laboratories of Drug Discovery and Technology Formulation, within a long-term collaboration with CNR. Italian excellence: the Dompé Hub in L’Aquila. Dompé has concentrated its manufacturing and research and development activities at its L’Aquila hub.
NGF was the first neurotrophic factor to be identified and purified and over the last fifty years, its role in neuronal development and its biological activity on neural tissue has been of great interest to science.
New management for the Dompé Ophthalmology Division | Dompé
Discovered in the s by Nobel Prize winner Rita Levi Montalcini, NGF belongs to the neurotrophins, a family of proteins that can play a crucial role in regulating the survival, development and functions of neurons, both at a formluation and peripheral level.
We suggest you to update it for free by following one of the these links, choosing the browser you prefer: Finally, the results of our tormulation studies are made available on public databases, such as the website www.
Currently being tested in Phase II clinical trials, the drug is designed to counteract in an innovative way the inflammatory reactions that characterise the early stage of type 1 diabetes.
One group received Oxervate, a second group received formupation eye drop with a different concentration of cenegermin, and the third group received an eye drop without cenegermin. The most common adverse reactions in patients taking Oxervate are eye pain, ocular hyperemia enlarged blood vessels in the white of the eyeseye inflammation and increased lacrimation watery eyes.
Click here to learn more. The Formulagion specialises in the production of therapeutic proteins, or recombinant vaccines, for human use. The packaging is divided into two phases. The hub, which operates in compliance with GMP rules, is authorised to manufacture products using recombinant DNA technology, i.
The application of Smart Factory concepts in the pharma context, in fact, is accompanied by certain peculiarities linked to qualitative and regulatory aspects.
The proNGF has an additional protein chain pro that has the difficult task of assisting the correct folding of the protein. It received European Union Approval in July, for the treatment of moderate to severe neurotrophic keratitis.
In this first phase the gene inserted in the bacterium for the production of the protein is rendered silent. The division works in close connection with the formlation community to make safe drugs available to patients that can meet their therapeutic needs.
You are going to leave this site. We suggest you to update it for free by following one of the these links, choosing the browser you prefer: Given its importance, the cell bank is also stored off-site, so as to guarantee its preservation in case of natural disasters. The native three-dimensional structure is fundamental in order to guarantee the correct biological activity of the mature NGF.
The release technologies studied in this field are also applied to the treatment of dermatological pathologies the ongoing projects concern the controlled release of proteins for the treatment of wounds and the protection of topical formulations containing active ingredients that, following exposure to sunlight, generate toxic species. Sorry, your blog cannot share posts by email.
Career Paths | Dompé
The prevalence of neurotrophic keratitis has been estimated to be less than fompe in 10, individuals. This makes it possible to guarantee the high quality standards formulagion by the pharmaceutical sector, which is heavily regulated. He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc. Primary packaging — in formulagion controlled air environment — in which the pharmaceutical product is inserted into the individual stick, packet or container.
In this phase the fermentation volume grows from a few litres initially up to litres, and in the end the proNGF gene is activated and begins the real protein production. One group was treated with Oxervate eye drops and the other group was treated with an eye drop without cenegermin.